American Journal of Cardiology最新文献

{"title":"Life-Threatening Ventricular Tachyarrhythmia in Isolated Cardiac Sarcoidosis Compared With Cardiac Sarcoidosis With Extracardiac Involvement.","authors":"Yoichi Takaya, Koji Nakagawa, Toru Miyoshi, Nobuhiro Nishii, Hiroshi Morita, Kazufumi Nakamura, Shinsuke Yuasa","doi":"10.1016/j.amjcard.2024.12.002","DOIUrl":"https://doi.org/10.1016/j.amjcard.2024.12.002","url":null,"abstract":"<p><p>Although isolated cardiac sarcoidosis (CS) is not uncommon, little is known about the risk of life-threatening ventricular tachyarrhythmia. We aimed to evaluate the incidence of ventricular tachyarrhythmia in patients with isolated CS. Ninety-four patients with CS were enrolled. Isolated CS was diagnosed by histological or clinical confirmation in the heart alone. The endpoint was sudden cardiac death, ventricular fibrillation, sustained ventricular tachycardia, or implantable cardioverter defibrillator (ICD) therapy for ventricular fibrillation or sustained ventricular tachycardia. Twenty-five patients were diagnosed with isolated CS, and 69 with CS with extracardiac involvement. As the initial cardiac manifestation leading to the CS diagnosis, 10 (40%) patients with isolated CS had ventricular tachyarrhythmia. Over the median follow-up of 48 months after the CS diagnosis, sudden cardiac death occurred in 2 (8%) patients with isolated CS. Ventricular fibrillation or sustained ventricular tachycardia, including ICD therapy, occurred in 15 (60%) patients with isolated CS and 13 (19%) with CS with extracardiac involvement. The rate of ventricular tachyarrhythmia was higher in patients with isolated CS than in those with CS with extracardiac involvement (log-rank, p < 0.01). Cox proportional hazard analysis showed that isolated CS was independently associated with ventricular tachyarrhythmia. Two or more ventricular tachyarrhythmias more frequently occurred in patients with isolated CS (52% vs 13%, p < 0.01). Electric storm more frequently occurred in patients with isolated CS (24% vs 6%, p = 0.01). In conclusion, patients with isolated CS have ventricular tachyarrhythmia at a higher rate, compared with those with CS with extracardiac involvement.</p>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142799103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns and Prognostic Impact of Post-Discharge Ischemic, Bleeding, and Heart Failure Events After Myocardial Infarction.","authors":"Shogo Okita, Yuichi Saito, Hiroaki Yaginuma, Kazunari Asada, Hiroki Goto, Osamu Hashimoto, Takanori Sato, Hideki Kitahara, Yoshio Kobayashi","doi":"10.1016/j.amjcard.2024.12.004","DOIUrl":"https://doi.org/10.1016/j.amjcard.2024.12.004","url":null,"abstract":"<p><p>Although the in-hospital prognosis after acute myocardial infarction (AMI) has considerably improved to date, ischemic, bleeding, and heart failure (HF) events after discharge remain clinical challenges. However, the pattern of such events is not fully understood in contemporary clinical practice. The present study aimed to evaluate the timing and prognostic impact of cardiovascular and bleeding events after AMI. This multicenter, retrospective registry included 2059 patients with AMI undergoing percutaneous coronary intervention. Patients were grouped according to their first events after discharge, consisting of ischemic events (recurrent AMI or ischemic stroke), major bleeding, and HF hospitalization, while those without such events were classified as the no cardiovascular event group. All-cause mortality after discharge and the ischemic, bleeding, and HF events were evaluated. Ischemic events, major bleedings, and HF hospitalization as their first clinical outcome measures after discharge occurred in 99 (4.8%), 57 (2.8%), and 75 (3.6%) patients during the median follow-up period of 538 days. Post-discharge mortality was highest in the major bleeding group, followed by the ischemic events, HF hospitalization, and no cardiovascular event groups. HF hospitalization occurred earlier than major bleeding and ischemic events after discharge. The mortality impact after the first events was greater in the major bleeding rather than ischemic events and HF hospitalization. In conclusion, patterns and prognostic impact of post-discharge outcomes differed significantly among ischemic, bleeding, and HF events, suggesting that timely and tailored follow-up may be needed after AMI.</p>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Course and Outcomes of Acute Heart Failure With Moderate-to-Severe Mitral or Tricuspid Regurgitation.","authors":"Sarah C Ashley, Muhammad Shahzeb Khan, Stephen J Greene","doi":"10.1016/j.amjcard.2024.11.034","DOIUrl":"10.1016/j.amjcard.2024.11.034","url":null,"abstract":"<p><p>Moderate-to-severe mitral regurgitation (MR) and tricuspid regurgitation (TR) are common in patients hospitalized with heart failure (HF) and have been associated with poor quality of life and increased mortality. The impact of these valve lesions on in-hospital decongestion and postdischarge outcomes is less clear. This study analyzed 617 patients hospitalized for acute HF in the Diuretic Optimization Strategies in Acute Heart Failure (DOSE-AHF), Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE-AHF), and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF) trials. We assessed biomarkers, physical examination findings, and symptom scores in 288 patients without moderate-to-severe regurgitation, 221 patients with moderate-to-severe MR, and 242 patients with moderate-to-severe TR to evaluate decongestion efficacy and outcomes. For patients with moderate-to-severe MR, there was no difference in weight loss, net fluid loss, or change in creatinine compared with those without moderate-to-severe regurgitation (all p >0.05 at 72 hours). For patients with moderate-to-severe TR, there was more weight loss (-4.77 vs -2.83 pounds at 24 hours, p = 0.029; -9.32 vs -6.99 pounds at 72 hours, p = 0.007), net fluid loss (-4,988 vs -4,581 ml, p = 0.008), and improvement in creatinine (-0.09 mg/100 ml vs +0.06 mg/100 ml at 72 hours, p = 0.002) than those without moderate-to-severe regurgitation. In those with and without moderate-to-severe regurgitation, there was no difference in the change in patient-reported dyspnea or global well-being (all p >0.05 at 72 or 96 hours). For postdischarge outcomes, compared with patients without moderate-to-severe regurgitation, moderate-to-severe MR was associated with a nonsignificant trend toward increased death, rehospitalization, or unscheduled clinic or emergency department visit 60 days after hospital discharge (48.4% vs 38.2% of patients, p = 0.098). This association was not clearly apparent in patients with moderate-to-severe TR (43.8% vs 38.2%, p = 0.407). In conclusion, patients with moderate-to-severe MR experienced similar in-hospital decongestion compared with those without significant regurgitation but had a trend toward worse postdischarge outcomes. Patients with moderate-to-severe TR experienced significantly more decongestion but this was not associated with incremental improvement in dyspnea, global well-being, or clinical outcomes.</p>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142790982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Illuminating the Safety of Ultrasound Contrast Agents.","authors":"Jordan B Strom, Sharon L Mulvagh, Thomas R Porter, Michael L Main, Paul A Grayburn","doi":"10.1016/j.amjcard.2024.11.035","DOIUrl":"https://doi.org/10.1016/j.amjcard.2024.11.035","url":null,"abstract":"<p><p>Echocardiography is an essential element for accurate and timely diagnosis of cardiac pathology. In this context, ultrasound enhancing agents (UEAs), are often essential for visualizing endocardial borders,¹ evaluating myocardial perfusion, characterizing intracardiac masses, and other applications. Although UEAs have been shown to be safe, rare serious adverse events (SAEs) have been reported. It is in this context that De La Fuente Gonzalez et al performed a systematic review evaluating randomized and observational data comparing the safety of UEA brands from 2018-2023. The authors conclude that \"Optison reduces risk of serious adverse events vs. Definity/Lumason.\" However, the data presented do not support such a conclusion, as will be discussed in this editorial. What can be concluded is that UEAs as a class are extremely safe with very rare SAEs. The use of UEAs during echocardiography are encouraged per guideline-directed indications based upon evidence-based reduction of misdiagnosis and duplicative testing.</p>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142783975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Matchmaker, Matchmaker, Find Me a Valve.","authors":"Elliot J Stein, David T Linker","doi":"10.1016/j.amjcard.2024.11.032","DOIUrl":"10.1016/j.amjcard.2024.11.032","url":null,"abstract":"","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142779158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of Bleeding, Thrombosis and Death among Atrial Fibrillation Patients Treated with Oral Anticoagulants Across Estimated Glomerular Filtration Rates.","authors":"Xinhai Huang, Donglin Xie, Jie Huang, Ruijuan Li, Qiaowei Zheng, Xiumei Liu, Hengfen Dai, Xiangsheng Lin, Yuxin Liu, Jun Su, Xiaomin Dong, Yanxian Lan, Cuifang You, Shuzheng Jiang, Jinhua Zhang","doi":"10.1016/j.amjcard.2024.11.033","DOIUrl":"10.1016/j.amjcard.2024.11.033","url":null,"abstract":"<p><p>There are limited data about the clinical benefits and harm of oral anticoagulants (OACs) for stroke prevention in patients with atrial fibrillation (AF) and chronic kidney disease using CKD-EPI creatinine equation for glomerular filtration rate (GFR) estimation in nuanced GFR stratification. We conducted a retrospective study in 12 centers in China and included 9,510 patients with AF. We grouped patients into the following estimated GFR (eGFR) categories: ≥60 (n = 7,616), 45 to 59 (n = 1,139), 30 to 44 (n = 474), and <30 (n = 281) ml/min/1.73 m². Logistic regression was used to the compare risks of major bleeding, minor bleeding, total bleeding, thrombosis, and all-cause deaths in patients with AF with eGFR 45 to 59, 30 to 44, <30 ml/min/1.73 m², and ≥60 ml/min/1.73 m² after taking OACs. Patients with AF treated with OACs with eGFR 45 to 59, 30 to 44, and <30 ml/min/1.73 m² had a significantly increased risk of all-cause deaths compared with eGFR ≥60 ml/min/1.73 m² (adjusted odds ratio [aOR] 1.326, 95% confidence interval [CI] 1.049 to 1.665, p = 0.016; aOR 1.634, 95% CI 1.197 to 2.200, p = 0.002; aOR 2.492, 95% CI 1.766 to 3.471, p <0.001; respectively). Higher eGFR was associated with a significantly lower risk of all-cause deaths (aOR 0.990, 95% CI 0.986 to 0.994, p <0.001) and major bleeding (aOR 0.988, 95% CI 0.979 to 0.998, p = 0.018). Direct OACs remarkably reduced risk of major bleeding in those with eGFR 30 to 44 ml/min/1.73 m² compared with warfarin. In conclusion, in patients with AF treated with OACs, patients with eGFR 45 to 59, 30 to 44, and <30 ml/min/1.73 m² had a significantly increased risk of all-cause deaths compared with eGFR ≥60 ml/min/1.73 m², and the risk of all-cause deaths increased with decreasing eGFR. Direct OACs are at least safe alternatives to warfarin in patients with AF with eGFR 30 to 44 ml/min/1.73 m².</p>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142779084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Floating but Not yet Landed: Are Drug-Coated Balloons for In-Stent Restenosis the Answer?","authors":"Georg Gussak, John J Lopez","doi":"10.1016/j.amjcard.2024.11.012","DOIUrl":"10.1016/j.amjcard.2024.11.012","url":null,"abstract":"","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142692633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fasting Versus Nonfasting Before Cardiac Catheterization: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","authors":"Muhammad Saad, Saad Ahmed Waqas, Jazza Aamir, Muhammad Umer Sohail, Ifrah Ansari, Anmol Mohan, Vikash Kumar, Chadi Alraies","doi":"10.1016/j.amjcard.2024.11.030","DOIUrl":"10.1016/j.amjcard.2024.11.030","url":null,"abstract":"<p><p>This meta-analysis compared postprocedural outcomes between fasting and nonfasting groups in patients who underwent cardiac catheterization. Online databases were searched up to September 2024 to identify studies comparing postprocedural outcomes in fasting and nonfasting groups. Data were meta-analyzed using a random-effects model to calculate the standardized mean differences (SMDs) and risk ratios (RRs) with 95% confidence intervals. A total of 7 randomized controlled trials with a total of 2,835 patients (1,433 fasting vs 1,402 nonfasting) were included. Nonfasting patients demonstrated significantly better patient satisfaction scores than fasting patients (SMD -0.72 [-1.33 to -0.12], p = 0.02). There were no significant differences between the fasting and nonfasting groups for nausea/vomiting (RR 1.15 [0.62 to 2.14], p = 0.66), hypoglycemia (RR 0.79 [0.46 to 1.35], p = 0.38), hospital length of stay (SMD -0.16 [-0.71 to 0.38], p = 0.55), aspiration pneumonia (RR 0.46 [0.06 to 3.57], p = 0.46), contrast-associated acute kidney injury (RR 1.48 [0.79 to 2.76], p = 0.22), 30-day mortality (RR 1.53 [0.49 to 4.80], p = 0.46), and hyperglycemia (RR 0.64 [0.34 to 1.19], p = 0.15). Nonfasting improved patient satisfaction and was just as safe as fasting in patients who underwent cardiac catheterization, showing no significant differences in key postprocedural outcomes. Future research should evaluate liberal fasting protocols in distinct populations to ensure safety and guide tailored recommendations.</p>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142754575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"External Validation of COAPT Risk Score in Patients Who Underwent Transcatheter Edge-To-Edge Repair of Severe, Functional Mitral Regurgitation: A Multicenter, Observational Italian-Polish Study.","authors":"Aleksandra Gąsecka, Karolina Jasińska-Gniadzik, Fabrizio D'Ascenzo, Filippo Angelini, Michał Łomiak, Jerzy Pręgowski, Zbigniew Chmielak, Piotr Kasprzyk, Jan Kasprzyk, Miłosz J Jaguszewski, Marcin Fijałkowski, Michal Chmielecki, Rafał Gałąska, Marcin Grabowski, Janusz Kochman, Adam Rdzanek, Łukasz Kołtowski, Monika Budnik, Radosław Piątkowski, Piotr Scisło, Agnieszka Kapłon-Cieślicka, Renata Główczyńska, Elena Cavallone, Antonio Montefusco, Claudia Raineri, Veronica Dusi, Pier Paolo Bocchino, Paolo Boretto, Simone Frea, Stefano Pidello, Gaetano Maria De Ferrari, Arkadiusz Pietrasik","doi":"10.1016/j.amjcard.2024.11.024","DOIUrl":"10.1016/j.amjcard.2024.11.024","url":null,"abstract":"<p><p>The Cardiovascular Outcomes Assessment for Heart Failure Patients with Functional Mitral Regurgitation (COAPT) risk score predicts the risk of death or hospitalization for heart failure within 2 years after transcatheter edge-to-edge repair (TEER) of mitral regurgitation (MR) using the MitraClip device. We performed an international validation of the score in patients who underwent TEER in Italian and Polish cardiology centers. Patients with severe functional MR who underwent TEER with MitraClip between March 2012 and July 2023 were included. Patients were categorized as COAPT-eligible or -noneligible based on the COAPT trial criteria. Clinical data were collected from medical records and the COAPT risk score was calculated for each patient. The primary end point was a composite of all-cause mortality and hospitalization for heart failure at the 2-year follow-up. Of 344 patients, 218 were COAPT-eligible (63%) and 126 were COAPT-noneligible (37%). A higher COAPT score correlated to increased risk of primary end point in the overall population (p <0.001) and COAPT-eligible (p = 0.020) and COAPT-noneligible groups (p = 0.042). The COAPT score had a poor predictive value for the primary end point in every group (area under the curve [AUC] ≤0.61 for all). It performed better in lower-risk patients (<4 points) than higher-risk patients (≥4 points) (AUC 0.658 vs AUC 0.523). The COAPT score was independently associated with an increased risk of primary end point in patients with <4 points (adjusted hazard ratio 1.338, 95% confidence interval 1.031 to 1.737, p = 0.028) but not those with higher score values. In conclusion, the COAPT risk score has a poor performance in COAPT-eligible and -noneligible patients with severe functional MR. The score performance depends on the patient baseline risk, with better accuracy in lower-risk patients.</p>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":" ","pages":"12-20"},"PeriodicalIF":2.3,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142754573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progress of Angiographic Cardiac Allograft Vasculopathy in Patients With Long-Term Transplantation: Longitudinal Evaluation of Its Association With Dyslipidemia Patterns.","authors":"David Grundmann, Janina Neubarth-Mayer, Christoph Müller, Finn Becker, Daniel Reichart, Konstantin Stark, Ulrich Grabmaier, Simon Deseive, Konstantinos D Rizas, Jörg Hausleiter, Christian Hagl, Julinda Mehilli, Steffen Massberg, Madeleine Orban","doi":"10.1016/j.amjcard.2024.11.031","DOIUrl":"10.1016/j.amjcard.2024.11.031","url":null,"abstract":"<p><p>Cardiac allograft vasculopathy (CAV) is a progressive disease with limited options for secondary prevention. Ways to manage lipid parameters and dyslipidemia patterns in care after transplantation remain unclear. In this longitudinal study, we included 32 patients with long-term heart transplantations (median interval after transplant 13.8 years) with angiographic manifest CAV. In 299 matched nonstented segments at 3 distinct time points ([TPs] 0 to 2, with median intervals of 2 years, respectively), progress of diameter stenosis (D%DS) defined CAV progress. Values above the median of maximal D%DS defined substantial CAV progress. Category of left ventricular ejection fraction was evaluated at TP0 and TP3 (2 years after TP2). Findings were correlated with dyslipidemia patterns at TP0, and lipid variations at follow-up (TP1 to TP3). Analyses included routine lipid assessment, and triglycerides/high-density lipoprotein-cholesterol ratio (TG/HDL-c) and atherogenic index of plasma (AIP). At TP1 and TP2, patients with increase of TG/HDL-c ≥0.1 (p = 0.02, respectively) and with increase of AIP (p = 0.01 and p = 0.049, respectively) presented a greater maximal D%DS. Dyslipidemia patterns at TP0 did not show a relevant association with CAV progress. At TP2, increase of TGs, TG/HDL-c, and AIP were associated with substantial CAV progress (odds ratio [OR] 5.0, p = 0.046, and OR 9.2, p = 0.01, OR 6.6, p = 0.02, respectively). At TP3, patients with CAV-related worsening of left ventricular ejection fraction category presented with a greater increase of TG/HDL-c (p = 0.03). Although findings at TP0 did not affect CAV progress, an increase of TG/HDL-c could define patients at greater risk of CAV progress and CAV-related deterioration of graft function.</p>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142754577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}